Lundbeck A/S
Lundbeck A/S
-5,18 %
245,10 DKK
-13,40
Kurs
245,10
Høj
258,50
Ændring
-5,18 %
Lav
245,10
Opdateret
21-08-2019
Åben
258,50
Nyheder om Lundbeck A/S
Factsheet for Lundbeck A/S
Company Profile
Description
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs worldwide, including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, and Onfi for epilepsy.
Key Stats
Website: http://www.lundbeck.com
Headquarter country: Denmark
Employees: 5.379
Market Cap (at close 20-08-2019): DKK 51B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 14,90 24,40 198,10 51,90 48,00
Forward Price/Earnings 14,40 16,20 48,10 69,00 43,70
Price/Free Cash Flow 11,20 19,40 23,30 420,10 40,20
Return on Assets 18,30 13,10 5,80 -24,20 -0,60
Return on Equity 29,60 24,00 13,10 -51,00 -1,10
Return on Invested Capital 29,40 22,70 10,70 -37,70 1,60
Dividend


Dividend/Share:8,00
Ex. Dividend Date:31-12-2018
Trailing Dividend Yield:4,45
Payout Ratio:70,30
Date Currency Amount
31-03-2019 DKK 12,00
31-03-2018 DKK 8,00
31-03-2017 DKK 2,45
31-03-2014 DKK 2,77
31-03-2013 DKK 2,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 18.117,00 17.234,00 15.634,00 14.594,00 13.468,00
Gross Profit 14,66 13,35 11,55 9,20 9,31
Gross Margin % 80,92% 77,48% 73,89% 63,03% 69,11%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 5.301,00 4.591,00 4.018,00 498,00 409,00
Net income 3.907,00 2.624,00 1.211,00 -5.694,00 -153,00
Basic Earnings Per Share 19,66 13,28 6,14 -28,98 -0,78
Operating Income 5,30 4,17 2,29 -6,82 0,10
Operating Margin % 29,26% 24,17% 14,66% -46,70% 0,74%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 5.981,00 4.045,00 3.126,00 197,00 1.610,00
Capital Expenditures -704,00 -725,00 -342,00 -2.956,00 -1.549,00
Free Cash Flow 5.277,00 3.320,00 2.784,00 -2.759,00 61,00
Balance Sheet

Assets 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Current Assets 11.649,00 8.844,00 7.524,00 7.660,00 9.386,00 11.363,00
Long Term Assets 11.362,00 10.912,00 12.686,00 13.665,00 16.251,00 12.286,00
Total Assets 23.011,00 19.756,00 20.210,00 21.325,00 25.637,00 23.649,00
Liabilities 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Total Current Liabilities 7.576,00 6.479,00 7.776,00 7.748,00 7.202,00 6.518,00
Long Term Liabilities 1.096,00 2.740,00 4.792,00
Total Liabilities 7.575,00 10.516,00 12.540,00
Equity 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Retained Earnings 12.507,00 10.170,00 7.772,00 6.296,00 11.898,00 12.694,00
Treasury Stock
Total Stockholder Equity 14.251,00 12.181,00 9.694,00 8.785,00 13.526,00 13.481,00
Net Tangible Assets 6.228,00 4.616,00 855,00 -1.009,00 856,00 4.404,00